These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30572939)

  • 1. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial.
    Wang F; Fan W; Peng J; Lu Z; Pan Z; Li L; Gao Y; Li H; Chen G; Wu X; Ding P; Zeng Z; Wan D
    Cancer Commun (Lond); 2018 Dec; 38(1):73. PubMed ID: 30572939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
    Fan WH; Wang FL; Lu ZH; Pan ZZ; Li LR; Gao YH; Chen G; Wu XJ; Ding PR; Zeng ZF; Wan DS
    Chin J Cancer; 2015 Jun; 34(9):394-403. PubMed ID: 26111932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 4. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
    Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer.
    Yeh CH; Chen MF; Lai CH; Huang WS; Lee SP; Chen WC
    Int J Clin Oncol; 2012 Oct; 17(5):482-90. PubMed ID: 21938495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
    JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial.
    Ng SS; Lee JF; Yiu RY; Li JC; Hon SS; Mak TW; Ngo DK; Leung WW; Leung KL
    Surg Endosc; 2014 Jan; 28(1):297-306. PubMed ID: 24013470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched Analysis.
    Shin YS; Park JH; Yoon SM; Kim JC; Yu CS; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Choi EK; Ahn SD; Lee SW; Kim JH
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):630-639. PubMed ID: 29678529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer.
    Callender GG; Das P; Rodriguez-Bigas MA; Skibber JM; Crane CH; Krishnan S; Delclos ME; Feig BW
    Ann Surg Oncol; 2010 Feb; 17(2):441-7. PubMed ID: 19847569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Chen PJ; Su WC; Chang TK; Chen YC; Li CC; Yin TC; Tsai HL; Ma CJ; Huang CW; Wang JY
    Asian J Surg; 2021 Jul; 44(7):957-963. PubMed ID: 33622595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.
    Peeters KC; Marijnen CA; Nagtegaal ID; Kranenbarg EK; Putter H; Wiggers T; Rutten H; Pahlman L; Glimelius B; Leer JW; van de Velde CJ;
    Ann Surg; 2007 Nov; 246(5):693-701. PubMed ID: 17968156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk.
    Lai IL; You JF; Chern YJ; Tsai WS; Chiang JM; Hsieh PS; Hung HY; Yeh CY; Chiang SF; Lai CC; Tang RP; Chen JS; Hsu YJ
    World J Surg Oncol; 2019 Dec; 17(1):212. PubMed ID: 31818295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
    Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
    Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
    Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy.
    Kim HJ; Song JH; Ahn HS; Choi BH; Jeong H; Choi HS; Lee YH; Kang KM; Jeong BK
    Int J Colorectal Dis; 2017 May; 32(5):723-727. PubMed ID: 27885479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.